Authors
Latest:
The Future of Frontline CAR T in Mantle Cell Lymphoma: Brad S. Kahl, MDThe professor of medicine at Washington University School of Medicine in St. Louis discussed the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.
Latest:
Further Research With Tab-Cel in EBV+ Post-Transplant Lymphoproliferative DiseaseAJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed further research with tab-cel, including study 205.
Latest:
Nausheen Ahmed, MD, on the Impact of Prior Treatments on the Safety of Brexu-celThe assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.
Latest:
Improving Patient Access to Cell Therapy Through Decentralized ManufacturingDecentralized manufacturing could transform cell therapy delivery by reducing delays, costs, and logistical hurdles to improve patient outcomes.
Latest:
Adrian Kilcoyne, MD, MPH, MBA, on Adjusting Expectations for Remission Rates in Non–CAR-T Cell Therapy TrialsThe chief medical officer of Cellularity discussed the big picture implications of a new analysis of patient samples from legacy studies evaluating MLASC therapy in Crohn disease.
Latest:
Next Steps With CAR T-Cell Therapy in Multiple Myeloma: Omar Castaneda Puglianini, MDThe hematologist and medical oncologist discussed next steps with CAR T-cell therapy in penta-refractory multiple myeloma.
Latest:
Natalie Goedeker, CPNP, on Supporting Gene Therapy’s Ascendance in Muscular DystrophiesThe nurse practitioner from Washington University in St. Louis discussed the practical considerations in gene therapy track she chaired at the 2023 MDA Conference.
Latest:
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCLThe associate professor of medicine at University of Colorado discussed data presented at ASCO 2024.
Latest:
Targeting Unmet Needs in Rare Dermatologic Diseases With Gene TherapyMatthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed FCX-013 for the potential treatment of scleroderma.
Latest:
Recognizing and Managing AEs in CAR T-Cell TherapyKelly Garvin, BSN, RN, OCN, discussed methods to communicate the benefits and risks of CAR T-cell therapy to patients and recognize AEs.
Latest:
Olivier Danos, PhD, on Enhancing Gene Therapy for DMDThe chief scientific officer at REGENXBIO discussed RGX-202 and the ongoing clinical trial.
Latest:
Overcoming Barriers to TIL Use in Patients With Solid TumorsClosing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
Latest:
John Murphy, PhD, on Using Gene Editing to Tackle Primary Hyperoxaluria Type 1The chief scientific officer of Arbor Biotechnologies discussed the company’s preclinical candidate ABO-101.
Latest:
A Review of Autologous Stem Cell Transplantation in AmyloidosisIuliana Vaxman, MD, and Angela Dispenzieri, MD, review eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.
Latest:
Kenji Fujita, MD, on Clinically Meaningful FST and MLMT Improvements in LCA1 With ATSN-101The chief medical officer at Atsena Therapeutics discussed updated, 6-month data from a phase 1/2 trial presented at ARVO 2023.
Latest:
Sharif Tabebordbar, PhD, on Improving In Vivo Gene Editing for DMDThe cofounder and chief executive officer of Kate Therapeutics discussed research that awarded him an Outstanding New Investigator at the ASGCT 2024 meeting.
Latest:
Alfonso Sabater, MD, PhD, on Further Research With Gene Therapy in Eye CareThe associate professor of clinical ophthalmology at University of Miami discussed the first topical application of gene therapy to the eye.
Latest:
Alice Zhou, MD, PhD, and Omar Butt, MD, PhD, on Surprising Associations With Neurotoxicity and Neurofilament LightThe medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.
Latest:
Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCLAlan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.
Latest:
Using Programmable Genomic Integration to Make Edits Big and SmallJohn Finn, PhD, the chief scientific officer of Tome Biosciences, discussed the company’s pipeline for its new technology.
Latest:
The Potential of CAR T-Cell Therapy in Adult ALLEunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.
Latest:
Expanding Study Populations of Cell Therapy in Sickle Cell Disease: Michael Grimley, MDThe medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.
Latest:
Wenjun "Tia" Li, on Reducing Swelling in Mouse Models of Rheumatoid Arthritis With Gene TherapyThe PhD candidate from University of North Carolina – Chapel Hill discussed preclinical research presented at ASGCT 2023.
Latest:
Krystof Bankiewicz, MD, PhD, on GDNF Gene Therapy for Parkinson’s and AADC DeficiencyThe professor at Ohio State University and University of California – San Francisco discussed investigations with different delivery methods of GDNF gene therapy.
Latest:
Targeting Hematological Malignancies With Autologous and Allogeneic Cell TherapiesThomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.
Latest:
Carlos A. Ramos, MD, on Alternatives to T-Cell TherapyThe professor of medicine at Baylor College of Medicine discussed research with NK-T cells and alternatives to αβ T-cells.
Latest:
Stem Cell Therapy Device Restores Insulin Production in T1 Diabetes: James Shapiro, MDThe Director of the Islet Transplant Program at the University of Alberta discussed the implantable VC-02 device's success in type 1 diabetes.
Latest:
Anelloviruses, a Potential Alternative to AAV for Gene TherapyChris Wright, MD, PhD, the chief medical officer and head of translational research at Ring Therapeutics, discussed research presented at ASGCT 2024.
